GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (WBO:ILMN) » Definitions » Net Income From Continuing Operations

Illumina (WBO:ILMN) Net Income From Continuing Operations : €-1,200 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Illumina Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Illumina's net income from continuing operations for the three months ended in Mar. 2024 was €-116 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-1,200 Mil.


Illumina Net Income From Continuing Operations Historical Data

The historical data trend for Illumina's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Net Income From Continuing Operations Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 891.00 539.23 674.37 -4,157.38 -1,064.64

Illumina Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.80 -215.98 -707.44 -160.48 -115.92

Illumina Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,200 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Illumina (WBO:ILMN) Business Description

Industry
Traded in Other Exchanges
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina (WBO:ILMN) Headlines

From GuruFocus

Q1 2023 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc 2022 Investor Day Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024